Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intellectual property issues of immune checkpoint inhibitors.

Literature DB >> 26466763

Intellectual property issues of immune checkpoint inhibitors.

Abstract

Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.

Entities: Disease

Keywords: CTLA4; Immune checkpoint inhibitors; Keytruda; Opdivo; PD-L1; PD1; Yervoy; antibody; patent

Mesh：

Substances：
Antineoplastic Agents

Year: 2015 PMID： 26466763 PMCID： PMC4966505 DOI： 10.1080/19420862.2015.1107688

Source DB: PubMed Journal: MAbs ISSN： 1942-0862 Impact factor: 5.857

22 in total

Review 1. Engineered protein scaffolds as next-generation antibody therapeutics.

Authors: Michaela Gebauer; Arne Skerra
Journal: Curr Opin Chem Biol Date: 2009-06-06 Impact factor: 8.822

2. Isolated DNA patent ban creates muddy waters for biomarkers and natural products.

Authors: Charlotte Harrison
Journal: Nat Rev Drug Discov Date: 2013-08 Impact factor: 84.694

3. Immune-checkpoint inhibitors march on, now in combinations.

Authors: Cormac Sheridan
Journal: Nat Biotechnol Date: 2014-04 Impact factor: 54.908

4. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

Authors: R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon
Journal: Proc Natl Acad Sci U S A Date: 2004-11-29 Impact factor: 11.205

5. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.

Authors: Derek Ng Tang; Yu Shen; Jingjing Sun; Sijin Wen; Jedd D Wolchok; Jianda Yuan; James P Allison; Padmanee Sharma
Journal: Cancer Immunol Res Date: 2013-07-31 Impact factor: 11.151

6. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors: Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal: N Engl J Med Date: 2014-12-06 Impact factor: 91.245

Intellectual property issues of immune checkpoint inhibitors.

Review 1. Engineered protein scaffolds as next-generation antibody therapeutics.

2. Isolated DNA patent ban creates muddy waters for biomarkers and natural products.

3. Immune-checkpoint inhibitors march on, now in combinations.

4. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

5. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.

6. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Review 7. CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

8. Enhancement of antitumor immunity by CTLA-4 blockade.

9. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.

10. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

1. Patent trend and competitive analysis of cancer immunotherapy in the United States.